Applied Food Technologies, Inc., a growth stage biotechnology company developing molecular diagnostics to address issues related to safety, science and technology in the food industry, was the first to develop DNA based diagnostics for use in the seafood industry for species identification and verification.
Contact: LeeAnn Applewhite, CEO, 386.418.3661, email@example.com, www.appliedfoodtechnologies.com
AxoGen (OTCBB:AXGN) is a biomedical company developing products that will allow surgeons to repair and regenerate peripheral nerves more successfully than ever before.
Contact: Karen Zaderej, CEO, 386.462.6800, firstname.lastname@example.org, www.axogeninc.com
Banyan Biomarkers is developing novel biomarker diagnostic and therapeutic products to address unmet clinical needs associated with organ injury with an initial focus on traumatic brain injury.
Contact: Dr. Jackson Streeter, CEO and CMO, 386.462.6699, email@example.com, www.banyanbio.com
EigenChem Technologies, Inc. is a concept-stage start-up company developing disruptive technologies for the cleantech and biotech business sectors with a focus on novel approaches to making quantum dots for energy and biomedical applications, advanced photochemical solar cells, and turning large-scale polymeric wastes into value-added products.
Contact: Polina Oliferenko, CEO, 352.792.4008, firstname.lastname@example.org, www.eigenchem.com
MLM Biologics, Inc. is a Florida-based medical device company with concentration in regenerative medicine (musculoskeletal deficiencies) and diagnostic medicine (oncology & cardiology). The company utilizes proprietary and licensed technologies to develop, promote and distribute medical devices, primarily a biologics platform. The goal is to deliver a product portfolio that is effective both clinically (evidence and market driven) and financially (cost competitive), and have the opportunity to serve the needs of masses of patients worldwide using non-conventional marketing and sales distribution strategies.
Contact: Chandra Nataraj, President, 352.514.4269, email@example.com, or Ken Harvey, Vice President, 352.378.3060, firstname.lastname@example.org
Pasteuria Bioscience, Inc. is an early-stage agricultural biotechnology company formed to address the world’s largest unmet pest-control problem: plant-parasitic nematodes with a proprietary technology that allows the in-vitro growth and sporulation of Pasteuria penetrans, a naturally-occurring nematode pathogen, for nematode control in crops ranging from high-value ornamentals to agronomic staples.
Contact: Kelly Smith, Head, 386.518.5060, email@example.com, www.pasteuriabio.com
Prevacus, Inc. is a drug development company working on prevention and treatment of mild traumatic brain injury (mTBI) or concussion. Every year 4-6 million people suffer from mTBIs many of which do not reach an emergency room and go unreported. Apart from analgesics for associated pain and anti-depressants, there are no approved pharmaceutical therapies for mTBI. Prevacus is formulating therapeutics for nasal delivery to ease use in the field and to maximize delivery to the brain. Prevasol is our flagship product. The active ingredient in Prevasol is a synthetic compound that simultaneously reduces edema, inflammation and oxidative stress.
Contact: Jake VanLandingham, CEO, 850.544.2962, firstname.lastname@example.org, www.prevacus.com
Prometheon Pharma, LLC, Like the mythological Greek god Prometheus who gave mankind the precious gift of fire, Prometheon Pharma, LLC is dedicated to developing novel therapeutics that address urgent and unmet global health care needs for the new millennium. We are currently developing our novel transdermal delivery system, the TopiconTM drug patch, which is the first truly passive patch technology that offers patients a painless, needle-free solution for daily injections. Our flagship product is the TopiconTMDM long-acting insulin patch. Our goal is to offer patients the choice of non-invasive therapeutic modalities to treat and prevent a broad range of common diseases that affect large populations. Contact: Stephen I. Hsu, MD, PhD, CEO and Chief Scientific Officer, 386.418.0320, email@example.com
Zenagene, Inc. is molecular biology company focused on the development of biomarkers to predict cancer risk, in particular for those like lung and pancreatic cancer for which there is no early detection and/or clinical methods for surveillance. In addition, Zenagene is developing agents which reverse the epigenetic silencing of the anticancer gene, Brahma (BRM). Such advances are needed to enhance our pursuit of personalized medicine.
Contact: David Reisman, CEO, 734.929.7503, firstname.lastname@example.org